A little more than a year after taking the helm, Emmanuel Ligner contends the provider of products and services to the life sciences industry is positioned for growth.
The new Lipid Innovation Center will manufacture pharmaceutical lipids for RNA medicines and other advanced therapies, with full production capacity expected by mid-2027.
The expanded authorization allows the German CDMO to manufacture sterile viral drug substances and investigational medicinal products, including advanced therapies.